PMID- 34625598
OWN - NLM
STAT- MEDLINE
DCOM- 20220125
LR  - 20221207
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Oct 8
TI  - Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a 
      randomized clinical trial.
PG  - 20062
LID - 10.1038/s41598-021-99527-y [doi]
LID - 20062
AB  - In this study, we investigated the effect of exenatide (EXE), a glucagon-like 
      peptide (GLP)-1 receptor agonist, on kidney function, obesity indices, and 
      glucose control in overweight/obese patients with type 2 diabetes mellitus 
      (T2DM). A total of 159 overweight/obese patients with T2DM were randomized to the 
      EXE group or insulin glargine (GLAR) control group for a total treatment period 
      of 24 weeks. EXE intervention significantly reduced the urine albumin 
      concentration (UAC) at week 12 and 24 endpoints (P < 0.001 at week 12 and 24). 
      The levels of the anthropometric, glucose and lipid parameters (TG and HDL-c), 
      and inflammation biomarkers (CRP and TNF-alpha) in the EXE group were improved at 
      12 weeks or 24 weeks, respectively. Meanwhile, a comparison between two groups 
      showed significant changes in anthropometric parameters, glucose parameters, 
      lipid parameters (TG and HDL-c), and Inflammation biomarkers (CRP, IL-6, and 
      TNF-alpha). Serum fibroblast growth factor 21 (FGF21) was increased in the EXE group 
      (P = 0.005) at week 24, and the change was significantly improved compared with 
      GLAR group (P = 0.003). Correlation network analysis showed that FGF21 had a more 
      central role in improving metabolism in the EXE group, and the change of FGF 21 
      was significantly negatively correlated with UAC at week 12 and week 24, 
      respectively (r = - 0.297, P = 0.010; r = - 0.294, P = 0.012). Our results showed 
      that EXE could help patients improve UAC, glycemic levels, and inflammatory 
      biomarkers after a follow-up period of 24 weeks intervention. These EXE effects 
      may be partly mediated by FGF 21, indicating that EXE is an effective and safe 
      way to control albuminuria in overweight/obese patients with T2DM.
CI  - (c) 2021. The Author(s).
FAU - Kang, Chao
AU  - Kang C
AD  - Department of Nutriology of The General Hospital of Western Theater Command, 
      Chengdu, Sichuan, China.
FAU - Qiao, Qiao
AU  - Qiao Q
AD  - Department of Endocrinology of Xinqiao Hospital, Army Medical University, 
      Chongqing, China.
FAU - Tong, Qiang
AU  - Tong Q
AD  - Department of Endocrinology of Xinqiao Hospital, Army Medical University, 
      Chongqing, China.
FAU - Bai, Qian
AU  - Bai Q
AD  - Department of Nutriology of Xinqiao Hospital, Army Medical University, Chongqing, 
      China.
FAU - Huang, Chen
AU  - Huang C
AD  - Department of Nutriology of Xinqiao Hospital, Army Medical University, Chongqing, 
      China.
FAU - Fan, Rong
AU  - Fan R
AD  - Department of Nutriology of Xinqiao Hospital, Army Medical University, Chongqing, 
      China.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Nutriology of Xinqiao Hospital, Army Medical University, Chongqing, 
      China.
FAU - Kaliannan, Kanakaraju
AU  - Kaliannan K
AD  - Laboratory of Lipid Medicine and Technology, Department of Medicine, 
      Massachusetts General Hospital and Harvard Medical School, Boston, USA.
FAU - Wang, Jian
AU  - Wang J
AD  - Department of Nutriology of Xinqiao Hospital, Army Medical University, Chongqing, 
      China. wangjianxq@hotmail.com.
FAU - Xu, Jing
AU  - Xu J
AD  - Department of Endocrinology of Xinqiao Hospital, Army Medical University, 
      Chongqing, China. 13512380018@163.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20211008
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (fibroblast growth factor 21)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Biomarkers/*blood
MH  - Blood Glucose/analysis
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism/pathology
MH  - Exenatide/*therapeutic use
MH  - Female
MH  - Fibroblast Growth Factors/metabolism
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Obesity/*physiopathology
MH  - Overweight/*physiopathology
MH  - Prognosis
MH  - Prospective Studies
PMC - PMC8501012
COIS- The authors declare no competing interests.
EDAT- 2021/10/10 06:00
MHDA- 2022/01/27 06:00
PMCR- 2021/10/08
CRDT- 2021/10/09 06:00
PHST- 2021/06/12 00:00 [received]
PHST- 2021/09/27 00:00 [accepted]
PHST- 2021/10/09 06:00 [entrez]
PHST- 2021/10/10 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2021/10/08 00:00 [pmc-release]
AID - 10.1038/s41598-021-99527-y [pii]
AID - 99527 [pii]
AID - 10.1038/s41598-021-99527-y [doi]
PST - epublish
SO  - Sci Rep. 2021 Oct 8;11(1):20062. doi: 10.1038/s41598-021-99527-y.